KR20230018431A - 갈렉틴-3 억제제 - Google Patents
갈렉틴-3 억제제 Download PDFInfo
- Publication number
- KR20230018431A KR20230018431A KR1020227045460A KR20227045460A KR20230018431A KR 20230018431 A KR20230018431 A KR 20230018431A KR 1020227045460 A KR1020227045460 A KR 1020227045460A KR 20227045460 A KR20227045460 A KR 20227045460A KR 20230018431 A KR20230018431 A KR 20230018431A
- Authority
- KR
- South Korea
- Prior art keywords
- independently
- mmol
- chloro
- oxoisoindolin
- conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063030968P | 2020-05-28 | 2020-05-28 | |
| US63/030,968 | 2020-05-28 | ||
| PCT/US2021/034454 WO2021242982A1 (en) | 2020-05-28 | 2021-05-27 | Galectin-3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230018431A true KR20230018431A (ko) | 2023-02-07 |
Family
ID=76502884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227045460A Pending KR20230018431A (ko) | 2020-05-28 | 2021-05-27 | 갈렉틴-3 억제제 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12291522B2 (https=) |
| EP (1) | EP4157833A1 (https=) |
| JP (1) | JP7772718B2 (https=) |
| KR (1) | KR20230018431A (https=) |
| CN (1) | CN115768768A (https=) |
| WO (1) | WO2021242982A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026002250A1 (zh) * | 2024-06-28 | 2026-01-02 | 上海济煜医药科技股份有限公司 | 四唑基取代的吡喃半乳糖苷衍生物及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| JP6904906B2 (ja) | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| ES2921500T3 (es) | 2015-11-09 | 2022-08-26 | Galecto Biotech Ab | 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas |
| MX2019007646A (es) * | 2016-12-23 | 2019-09-06 | Arvinas Operations Inc | Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso. |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| EP3652329B1 (en) * | 2017-07-12 | 2023-10-04 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| WO2019067702A1 (en) * | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| CA3092677A1 (en) * | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| JP7190513B2 (ja) | 2018-06-15 | 2022-12-15 | ブリストル－マイヤーズ スクイブ カンパニー | ガレクチン－３抑制剤を模したテトラヒドロピラン系チオ二糖類 |
| MX2021001957A (es) * | 2018-08-22 | 2021-07-15 | Cullgen Shanghai Inc | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). |
-
2021
- 2021-05-27 EP EP21733338.4A patent/EP4157833A1/en active Pending
- 2021-05-27 KR KR1020227045460A patent/KR20230018431A/ko active Pending
- 2021-05-27 CN CN202180038169.4A patent/CN115768768A/zh active Pending
- 2021-05-27 US US17/927,426 patent/US12291522B2/en active Active
- 2021-05-27 WO PCT/US2021/034454 patent/WO2021242982A1/en not_active Ceased
- 2021-05-27 JP JP2022572736A patent/JP7772718B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023527396A (ja) | 2023-06-28 |
| EP4157833A1 (en) | 2023-04-05 |
| US12291522B2 (en) | 2025-05-06 |
| JP7772718B2 (ja) | 2025-11-18 |
| US20230303538A1 (en) | 2023-09-28 |
| WO2021242982A1 (en) | 2021-12-02 |
| CN115768768A (zh) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7530128B2 (ja) | Ｆｇｆｒ阻害剤化合物及びその使用 | |
| KR102890853B1 (ko) | 갈렉틴-3의 소분자 억제제 | |
| KR102921972B1 (ko) | P2x3 억제제로서 아미노 퀴나졸린 유도체 | |
| JP6759514B2 (ja) | ブロモドメインに対して活性な化合物 | |
| CN103415513B (zh) | 白三烯产物的苯并二氧杂环己烷抑制剂 | |
| CN117858878A (zh) | N-环丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途 | |
| TW202227410A (zh) | 作為glp-1r促效劑之化合物 | |
| JP2024534610A (ja) | 多環式縮合環誘導体およびその利用 | |
| AU2014248763B2 (en) | Substituted piperidine compounds and their use as orexin receptor modulators | |
| WO2024214038A1 (en) | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof | |
| KR20250121029A (ko) | 두드러기 치료를 위한 야생형 c-kit 키나제 억제제로서의 n-페닐-피라졸로[1,5-a]피리딘-3-카르복사미드 유도체 | |
| TW201734005A (zh) | 用於治療纖維化之新穎化合物及其醫藥組合物 | |
| TW201315727A (zh) | 尿嘧啶衍生物及其醫藥用途 | |
| ES2984075T3 (es) | Inhibidores de moléculas pequeñas de galectina-3 | |
| TW202444385A (zh) | Ｅｇｆｒ降解劑、其藥物組成物及其用途 | |
| TW202246243A (zh) | 胺基嘧啶化合物及其使用方法 | |
| KR20230018431A (ko) | 갈렉틴-3 억제제 | |
| CN115109061A (zh) | 三环化合物 | |
| US12275718B2 (en) | Small molecule inhibitors of galectin-3 | |
| CA2890852A1 (en) | Crystalline forms of (1s)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol | |
| WO2026078670A1 (en) | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists | |
| CN116761801A (zh) | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 | |
| HK40039964A (en) | Tricyclic compounds | |
| HK1187334A (en) | Benzodioxane inhibitors of leukotriene production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |